MobiHealthNews

Study finds Pear’s reSET-O could lower costs of treating opioid use disorder

Pear Therapeutics' reSET-O, a prescription app for treating opioid use disorder, may lower patients’ health care costs, compared with patients who don’t use the app, according to a study published in ...
MobiHealthNews

Patients that got a 'refill' of Pear's reSET-O demonstrated high rates of abstinence

Out of a group of 3,817 people who completed a 12-week prescription of reSET-O, 643 were prescribed a refill of another 12 weeks. For those who completed a total of 24 weeks of treatment, abstinence ...
BioWorld

Data shows Pear’s Reset-O significantly reduces health care utilization in patients with opioid use disorder

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...
Business Wire

PursueCare Introduces RESET ® and RESET-O ® —FDA-Authorized Digital Therapeutics for Addiction Treatment

MIDDLETOWN, Conn.--(BUSINESS WIRE)--PursueCare, a leader in virtual addiction treatment, today announced the rollout of RESET ® and RESET-O ®, the only FDA-authorized prescription digital therapeutics ...
Business Wire

Pear Therapeutics and Serve You Rx Announce Formulary Coverage for Prescription Digital Therapeutics reSET® & reSET-O® and People with Substance and Opioid Use Disorders

reSET-O is intended to increase retention of patients with Opioid Use Disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that ...
Nasdaq

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O®

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...
Nasdaq

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced ...
BioWorld

Data shows Pear’s Reset-O significantly reduces health care utilization in patients with opioid use disorder

Pear Therapeutics Inc. released nine-month, real-world data showing long-term reduction in costly health care utilization categories, including inpatient stays and emergency department visits, in ...